Anavex Life Sciences Corp (AVXL)

[sokol]

As I understand it (0rveko is much more knowledgable than me) a new drug once approved may be entitled to limited exclusivity of something like 4-5 years regardless of a patent. However, Orveko indicated that there is an old patent application Anavex has on file for 2-73 alone as I recall. That patent has been dormant for a number of years. Anavex certainly would not want to abandon that patent application assuming it still exists.

Orveko has pointed out that A2-73 is currently protected by one patent related to its use as a combination therapy for the treatment of melanoma, but that does not protect 2-73 as a mono-therapy.

Of course, there may be quite a few other patent applications as someone on this board pointed out. I believe they were referring to combination patents.

Plus, there is something like a 7 year exclusivity for Orphan drug approval -- approval of 2-73 for Rhett Syndrome, etc.

Lastly, Anavex has good patent attorney representation. Therefore, I believe they are diligently pursuing all sorts of patent protection including protection for A3-71 -- another Anavex drug candidate.